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Summary
Cystic fibrosis (CF) is one of the most common genetic
disorders. Mutations of the cystic fibrosis transmembrane
regulator causes dysfunction of epithelial membranes with-
in the gastrointestinal and respiratory system. Patients with
CF are known to be at risk for gastrointestinal malignan-
cies, and lung transplantation further increases this risk. We
report a case series of three CF patients who developed ad-
enocarcinoma of the gastrointestinal tract in the posttrans-
plant setting. One of these case histories describes a gastric
cancer, which is a novel and to date unreported observa-
tion. These data emphasise the importance of checking CF
patients for the development of abdominal complications
following lung transplantation.
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Introduction
Cystic fibrosis (CF) is one of the most common genetic dis-
orders. CF is caused by autosomal recessive mutations of
the cystic fibrosis transmembrane regulator (CFTR), which
cause dysfunction of epithelial membranes within the
gastrointestinal and respiratory systems [1]. Following im-
provement in disease management, survival of CF patients
has increased significantly in past decades. The median
predicted survival for CF patients in the United States has
increased by almost 10 years, from age 31.3 years in 2002
to 41.1 years in 2012 (Cystic Fibrosis Foundation,
www.cfff.org). According to a prediction model, children
born with CF in 2000 have a median survival of 50 years
[2, 3]. However, owing to chronic airway infection, hae-
moptysis, development of pulmonary hypertension and res-
piratory failure, CF patients remain one of the most im-
portant groups undergoing lung transplantation (LTx) [4].
LTx is the ultimate therapy for end-stage CF lung disease
[5] and we and others have demonstrated a survival benefit
for CF patients undergoing this therapy [6–8]. The overall
cancer risk in nontransplanted CF patients is similar to the
background risk of the normal population, with a stand-
ardised incidence ratio (SIR) of 1.1. In transplanted CF
patients more tumours have been observed than expected
(SIR 2.7). In both groups, the risk is particularly high for
gastrointestinal tumours (SIR 3.5 in nontransplanted and
SIR 17.3 in transplanted patients) [9–11].
In this context, our group has previously described the case
of a lung transplanted CF patient developing pancreatic
cancer [12]. Here we extend and discuss this series with
two additional CF patients who developed adenocarcinoma
of the gastrointestinal tract following LTx.
Case 1
A 42-year-old male CF patient developed metastatic
cholangiocarcinoma 5 years following bilateral LTx. Dia-
gnosis of CF was made at the age of 4 years (unknown
genetic). As a result of progressive CF lung disease, he
underwent LTx in 2002 (at the age of 34 years). Apart
from pancreatic insufficiency, the medical history, with re-
gards to the gastrointestinal tract, was remarkable for a
cholecystectomy in 1988 which was performed owing to
gallstone-induced cholecystitis.
Maintenance immunosuppression after LTx at our centre
consisted of a triple combination therapy with prednisone
(PDN), ciclosporin (CSA) and mycophenolate mofetil
(MMF). Because of the development of chronic lung allo-
graft dysfunction (CLAD) 3 years after LTPL, CSA was
switched to tacrolimus (TAC) and extracorporeal pho-
topheresis (ECP) was started. Seven years after transplant-
ation, the patient developed recurrent episodes of fever
and elevation of C-reactive protein levels without signs of
infection. Abdominal ultrasound and magnetic resonance
imaging (MRI) studies showed a 5x4 cm lesion of the left
liver lobe with stenosis of the left ductus hepaticus. After
the exclusion of distant metastasis using positron emission
tomography-computed tomography (PET-CT), a resection
of the extrahepatic bile ducts with roux-en-Y hepaticoje-
junostomy and left extended hemihepatectomy were per-
formed. The histology of the resected specimen revealed a
moderately differentiated adenocarcinoma of the extrahep-
atic bile duct (cholangiocarcinoma; pT3, pN1, G2, cM0).
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In this scenario, an interdisciplinary panel judged adjuvant
chemotherapy not to be a valuable option because of the
high risk of a relapse under immunosuppressive therapy.
A follow-up CT chest scan 7 months after tumour resection
showed bilateral lung lesions, whose radiological appear-
ance was compatible with pulmonary metastasis. Palliative
chemotherapy using gemcitabine and, when liver and bone
lesions developed, second-line therapy with oxaliplatin and
capecitabine was initiated. Unfortunately, the patient died
18 months after tumour surgery as a result of tumour pro-
gression and liver failure. In the last 12 months the median
trough (C0) TAC level was 11.3 ng/ml (target level 8–10
ng/ml), the MMF dose 500 mg BID and the PDN dose 7.5
mg ID (maintenance dose 0.1 mg/kg/day, body weight 75
kg),
Case 2
A 27-year-old female CF patient developed metastatic
gastric adenocarcinoma 9½ years after bilateral LTx. The
diagnosis of CF (homozygous F508del) was made at the
age of 9 months because of recurrent pulmonary infections.
After the age of 6 years, CF lung disease progressed and,
finally, the patient underwent LTx at the age of 17 in 2004.
Maintenance immunosuppression consisted of a triple
combination therapy with PDN, CSA and MMF. Three
years after LTx a persistent gastric fistula following gast-
rostomy tube removal resulted in an excision of the fistula
and a subtotal gastrectomy. An upper gastrointestinal endo-
Figure 1
Positron emission tomography-computed tomography scan
showing fluorodeoxyglucose uptake in the liver, bones and lymph
nodes (highlighted Virchow’s node in the left supraclavicular area).
scopy performed 4 years later showed discrete inflamma-
tion and fibrosis of the residual stomach tissue. The patient
suffered repeatedly from severe constipation owing to epis-
odes of distal intestinal obstructive syndrome (DIOS).
In August 2013, an abdominal ultrasound was performed
because of diffuse epigastric pain, which showed several
hepatic lesions. The MRI revealed coeliac, retroperitoneal
and hilar hepatic lymphadenopathy. PET-CT detected
fluorodeoxyglucose (FDG)-enriching lesions in the bones
and in the supraclavicular lymph nodes (“Virchow’s node”,
fig. 1). Fine needle aspiration of the latter showed adeno-
carcinoma cells, probably of gastrointestinal origin. Endo-
scopy confirmed the presence of a gastric tumour, which
was found to be a poorly differentiated adenocarcinoma
on biopsy. Probably as a result of paraneoplastic thrombo-
philia, the patient developed multiple venous thromboses
and a fatal event of pulmonary embolism with fulminant
right heart failure led to death. In the previous 12 months,
the median trough (C0) CSA level was 44 μmg/l (target
level calculated from the area under the concentration-time
curve [AUC]: 50–70 μg/l), the MMF dose 1000 mg BID
and the PDN dose 5 mg ID (maintenance dose 0.1 mg/kg/
day, body weight 35 kg).
Case 3
This case was described previously [12]. Briefly, an
18-year-old female CF patient developed metastatic pan-
creatic cancer 6 years after LTx. She was diagnosed with
CF at the age of 7 weeks because of failure to thrive (un-
known genetic). In 1999, she underwent bilateral LTx at the
age of 12 owing to advanced CF lung disease. Maintenance
immunosuppression consisted of triple combination ther-
apy with PDN, CSA and MMF. Therapy with somatropin
was started in 2002 because of growth retardation and low
serum levels of insulin-like growth factor-1 (IGF-1).
In April 2004, the patient was hospitalised owing to symp-
tomatic choledocholithiasis. Symptoms and cholestasis re-
solved with conservative therapy. Nine months later, she
again developed upper abdominal pain and elevated cho-
lestatic parameters. Abdominal CT revealed dilated intra-
and extrahepatic bile ducts, an enlarged pancreatic head
and an atrophic pancreatic corpus/tail. Transhepatic
cholangiography with insertion of a percutaneous drain
was performed and detected a massive dilatation of the
ductus choledochus with a long distal stenosis. The patient
underwent laparotomy; rapid section diagnosis of the pan-
creatic head revealed an adenocarcinoma. Pancre-
aticoduodenectomy was performed. The histology of the
resected specimen confirmed a poorly differentiated ductal
pancreatic adenocarcinoma with involvement of regional
lymph nodes (pT3, pN1, cMO). One month later, liver le-
sions occurred and fine needle aspiration obtained malig-
nant cells. Palliative chemotherapy with gemcitabine was
initiated. After four cycles of chemotherapy, the patient de-
cided to stop therapy and died shortly after. In the last 12
months, the median trough (C0) CSA level was 191 μg/l
(target level calculated from the AUC: 160–190 μg/l), the
MMF dose 500 mg BID and the PDN dose 5 mg ID (main-
tenance dose 0.1 mg/kg/day, body weight 43 kg).
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Discussion
In our cohort of 100 CF patients undergoing lung trans-
plantation between 1992 and 2009 [13], three patients de-
veloped digestive tract cancer. This observation suggests an
excess of cancer in an organ system known to be affected
by CF. The reasons for the organ-specific increase of can-
cer rate in CF patients remain unclear.
The first case of a CF patient with gastrointestinal cancer
was described in 1982, an adult with an extrahepatic biliary
tract cancer [14]. The largest dataset that is currently avail-
able on the association between CF and cancer was pub-
lished in 2013 [9], in which Maisonneuve et al. followed
more than 40,000 CF patients who were registered at any of
the 110 centres in the United States accredited by the Cystic
Fibrosis Foundation during the period from 1990 to 2009.
The overall cancer risk in non-transplanted patients was
similar to the expected incidence rates in the general popu-
lation observed by the National Cancer Institute (SIR 1.1).
Following transplantation (92% of transplanted CF patients
received a lung transplant), the risk of developing a solid
cancer was, however, found to be increased. (SIR 2.7) This
study confirms findings from previous studies [10] that re-
ported an increased risk (SIR 17.3) of digestive tract cancer
in CF patients, especially following transplantation.
Colon cancer represents the most common malignancy in
CF patients, both in non-transplanted and in lung trans-
planted patients (SIR 6.2 and SIR 30.1) [9–11, 15, 16].
The immunosuppressive medications used after LTx can
cause adverse gastrointestinal reactions including diarrhoea
and intestinal infections [15]. These mechanisms may con-
tribute to intestinal carcinogenesis. However, after LTx,
in non-CF transplant recipients, colon cancer is less fre-
quently observed than in CF transplant recipients [15].
Analysis of national databases in the UK and US from re-
cipients of LTx for any indication showed higher inciden-
ces of lung and bronchial cancer and posttransplant lymph-
oproliferative disorder (PTLD) than colorectal cancer [17,
18]. Of interest, CF patients who underwent screening
colonoscopy before the age of 50 years had a higher pre-
valence of both adenomas and advanced adenomas as com-
pared with non-CF patients in the same age group [16,
19]. In all of these studies, retrospective risk calculation
is potentially limited by the inclusion of older CF patients
that might bear genotypes encoding for milder pulmonary
phenotypes and a lower risk to develop cancers.
The factors that predispose CF patients to develop more ad-
enomas than the general population and more gastrointest-
inal cancers following LTx than lung transplanted patients
with other diagnoses are unknown, but it has been sugges-
ted that the localisation and expression of the CFTR gene
might play a role [11]. Profound changes in the biology
of epithelial cells and physiology of mucosal surfaces due
to CFTR deficiency have been described [16]. In human
foetal tissues, the highest levels of CFTR messenger RNA
are seen in defined areas of the developing pancreas, liv-
er, gall bladder and intestine [20]. The importance of the
CFTR gene in the development of cancer is highlighted by
the observation that homozygous mutations in the allelic
variant F508del carry a higher risk for CF patients to de-
velop colon cancer [10]. Moreover, mutations within the
CFTR gene cause abnormal mucous production in exocrine
glands, which, in turn, leads to obstruction with resultant
duct dilatation and tissue damage. The resulting inflamma-
tion of the pancreatic tissue may represent a procarcinogen-
ic stimulus [12]. It remains unclear, however, whether other
factors contributed to the development of malignancies in
our young female patient, such as the long-term application
of exogenous somatropin. An increased risk for cholan-
giocarcinoma is also found among patients with gallstone
disease, and gallstones are frequently found in patients with
CF. However, only few cases of cholangiocarcinoma in pa-
tients with CF and especially after lung transplantation are
known [9, 21, 22]. Whether in our second case of a patient
with gastric adenocarcinoma, the mechanical stress and the
consecutive inflammation following subtotal gastrectomy
resulted in carcinogenic transformation is unclear, but this
provides a potential explanation.
Of interest, a multicentre trial demonstrated antitumour ef-
fects by switching from calcineurin inhibitors to sirolimus,
an inhibitor of mammalian target of rapamycin (mTOR), in
kidney transplant recipients with squamous cell skin cancer
[23]. In addition in-vitro studies targeting the mTOR path-
way for colorectal cancer have provided promising per-
spectives [24]. Whether a switch from a calcineurin to an
mTOR inhibitor might be a therapeutic strategy in lung
transplanted CF patients with intestinal cancers remains,
however, unclear at the moment.
In conclusion we report three cases of adenocarcinoma
of the gastrointestinal tract in CF patients following LTx.
These data highlight the need for an increased awareness of
such complications in all lung transplant recipients present-
ing with abdominal symptoms. Moreover, these cases em-
phasise that patients under immunosuppressive therapies
following lung transplantation are expected to develop
posttransplant lymphoproliferative disorder but, as shown
previously [9] and confirmed by these case series, there
is an increased risk for the development of solid cancers
in the gastrointestinal tract. Although such an association
has been suggested by studies that showed an increase in
the rate of colon cancer in lung transplanted CF patients as
compared with non-CF patients, the case of a gastric can-
cer is a novel observation. As mentioned, our group has
already published the case report on the CF patient with a
pancreatic cancer (case 3), which, to the best of our know-
ledge is still the only published case [12].
Routine colonoscopy in CF patients is a controversial issue
and is not recommended according to the European con-
sensus of 2005 [25]. As such, it is not performed at our
institution. During pretransplant evaluation in our centre,
we perform upper and lower gastrointestinal endoscopy as
screening for gastrointestinal cancer in all patients older
than 50 years with suggestive symptoms or a positive
faecal occult blood test. This case series should increase
the awareness of physicians for the increased risk of
gastrointestinal tumours in lung transplanted CF patients.
In conclusion, the transplant community might consider
whether endoscopic investigations should be performed as
a baseline investigation before lung transplantation in all
CF patients [10].
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Figures (large format)
Figure 1
Positron emission tomography-computed tomography scan showing fluorodeoxyglucose uptake in the liver, bones and lymph nodes (highlighted
Virchow’s node in the left supraclavicular area).
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